MOZOBIL

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug MOZOBIL contains one active pharmaceutical ingredient (API):

1	Plerixafor UNII S915P5499N - PLERIXAFOR
	Plerixafor induces leukocytosis and elevations in circulating haematopoietic progenitor cell levels due to a disruption of CXCR4 binding to its cognate ligand, known as CXCL12, resulting in the appearance of both mature and pluripotent cells in the systemic circulation. CD34+ cells mobilised by plerixafor are functional and capable of engraftment with long-term repopulating capacity.
	Read more about Plerixafor

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MOZOBIL Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AX16	Plerixafor	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AX Other immunostimulants
Discover more medicines within L03AX16

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10083Q, 10084R
BR	Câmara de Regulação do Mercado de Medicamentos	502818120078617, 576720020056417
CA	Health Products and Food Branch	02377225
EE	Ravimiamet	1433900
ES	Centro de información online de medicamentos de la AEMPS	09537001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	048505
FR	Base de données publique des médicaments	60148167
GB	Medicines & Healthcare Products Regulatory Agency	161854
HK	Department of Health Drug Office	60176
IL	מִשְׂרַד הַבְּרִיאוּת	6406
IT	Agenzia del Farmaco	039587011
JP	医薬品医療機器総合機構	3399413A1021
LT	Valstybinė vaistų kontrolės tarnyba	1050715
NL	Z-Index G-Standaard, PRK	131156
NZ	Medicines and Medical Devices Safety Authority	16976
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W54580001
SG	Health Sciences Authority	13894P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699809779174
US	FDA, National Drug Code	0024-5862
ZA	Health Products Regulatory Authority	44/32.2/0546